Skip to content

San Gabriel Valley Tribune

80°F
Wednesday, March 11th 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

0.5649 +0.0941 (+19.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jaguar Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts
Via ACCESS Newswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants
Via ACCESS Newswire
News headline image
Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1
Via ACCESS Newswire
News headline image
Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend
Via ACCESS Newswire
News headline image
Jaguar Health Announces a Special One-time Stock Dividend
Via ACCESS Newswire
Monday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi
Via ACCESS Newswire
Here are the top movers in Tuesday's session. ↗
Via Chartmill
Unusual volume stocks are being observed in Tuesday's session. ↗
Via Chartmill
Tuesday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
Which stocks are moving after the closing bell on Monday? ↗
Via Chartmill
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Via Chartmill
Which stocks are experiencing notable movement on Friday? ↗
Via Chartmill
Curious about the most active stocks on Friday? ↗
Via Chartmill
News headline image
The Surge In Jaguar Health Stock: What&#39;s Happening Now? ↗
Jaguar Health Inc (NASDAQ:JAGX) subsidiary, Napo Pharmaceuticals, has struck a new licensing deal with Woodward Specialty. 
Via Benzinga
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
Get insights into the top gainers and losers of Friday's pre-market session. ↗
Via Chartmill
News headline image
Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts
Via ACCESS Newswire
Unusual volume stocks are being observed in Tuesday's session. ↗
Via Chartmill
News headline image
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
Via ACCESS Newswire
News headline image
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication
Via ACCESS Newswire
News headline image
Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Via ACCESS Newswire
News headline image
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Via ACCESS Newswire
News headline image
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Via ACCESS Newswire
News headline image
Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders
Via ACCESS Newswire
News headline image
Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.